Neoadjuvant Chemo and Concurrent Chemoradiation Is a Safe, Effective Bladder-Sparing Approach in Nonmetastatic MIBC
Some Patients With Kidney Cancer Can Stop Combination Treatment After Two Years, Fox Chase Cancer Center Study Finds
FDA Grants Priority Review to Dordaviprone in Recurrent H3K27M+ Diffuse Glioma
The Heart of the Matter: Unraveling the Link Between CVD and Breast Cancer for American Heart Month